WORLD JOURNAL OF ADVANCE
HEALTHCARE RESEARCH

*Nabeel A. K. A. Abo, Ahmed M. A. Albakr and Dhuha M. M. Al-Hayaw 

ABSTRACT

Background: Anastrazole is widely prescribed in recent years as a hormonal therapy for postmenopausal breast cancer women and as a new alternative for Tamoxifen. Aim of the study: is to measure estradiol levels in postmenopausal breast cancer women treated with anastrazole and compare them according to body mass index (BMI). To find out the level of FSH in those patients and to correlate the level of FSH with estradiol. Subjects and Methods: Twenty postmenopausal breast cancer women were tested for estradiol and FSH level using immunoassays retrospectively and patients were grouped according to their BMI. 10 other postmenopausal breast cancer women were also tested who didn’t receive the therapy and taking them as a control group. Results: The results revealed that only 10% of the postmenopausal breast cancer women had a normal BMI. The overweight and obese patients represent the highest percentages. Estradiol levels in very obese postmenopausal breast cancer women were significantly higher than estradiol level in those overweight or less obese patients. While the reverse was noticed with FSH level, that’s FSH level were less elevated in very obese women than in less obese or overweight postmenopausal breast cancer women. Conclusion: Anastrazole is less effective in reducing estradiol level in obese postmenopausal breast cancer women and it’s less effective as BMI increased. Anastrazole is less reducing FSH level in obese patients compared to normal weight patients.